Delving into the Latest Updates on BMS-433771 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BMS-356188, BMS-433771, BMS-505321

Target

RSV F protein

Action

inhibitors

Mechanism

Respiratory syncytial virus F protein inhibitors

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Respiratory Syncytial Virus Infections

Originator Organization

Bristol Myers Squibb Co.

Active Organization-

Inactive Organization

Bristol Myers Squibb Co.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC21H23N5O2

InChIKeyKSHJXDWYTZJUEI-UHFFFAOYSA-N

CAS Registry543700-68-1

Author: Rückert, Jessica ; Gunesch, Antonia P. ; Fischer, Nicole ; Zhang, Xiaoyu ; Friesland, Martina ; Kosch, Christina ; Duprex, W. Paul ; Huang, Jiabin ; Blockus, Sebastian ; Haid, Sibylle ; Hirsch, Anna K. H. ; Grethe, Christina ; Empting, Martin ; Kühnel, Anne ; Trummer, Sofie B. ; Sake, Svenja M. ; Schulz, Thomas F. ; Rameix-Welti, Marie-Anne ; Pietschmann, Thomas

Human respiratory syncytial virus (hRSV) infection is a leading cause of severe respiratory tract infections. Effective, directly acting antivirals against hRSV are not available.

27 Sep 2021·Journal of virologyQ2 · MEDICINE

Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein

Q2 · MEDICINE

Article

Author: Wang, Ying ; Ye, Wencai ; Song, Qiaoyun ; Li, Yueyue ; Li, Manmei ; Li, Yaolan ; Tang, Wei ; Wang, Ziqin ; Zhang, Qiwei

Respiratory syncytial virus (RSV) causes serious respiratory tract disease in children and the elderly. Therapeutics against RSV infection are urgently needed.

16 Dec 2020·Antimicrobial agents and chemotherapyQ2 · MEDICINE

Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants

Q2 · MEDICINE

Article

Author: Honma, Yusuke ; Yoshida, Ippei ; Arikawa, Kaho ; Yoshinaga, Mitsukane ; Inatani, Shoko ; Sugiyama, Hiroyuki

Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in early childhood. However, no vaccines have yet been approved for prevention of RSV infection, and the treatment options are limited. Therefore, development of effective and safe anti-RSV drugs is needed. In this study, we evaluated the antiviral activity and mechanism of action of a novel macrocyclic anti-RSV compound, TP0591816. TP0591816 showed significant antiviral activities against both subgroup A and subgroup B RSV, while exerting no cytotoxicity.

100 Deals associated with BMS-433771

Login to view more data